Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation
Introduction Androgenetic alopecia is a stressful condition for males. Minoxidil 2% and 5% have been FDA approved for treatment of this condition. In literature, all studies have compared minoxidil 5% with 2%. Although other concentrations (2% to 12.5%) are available nowadays, we believe our study i...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-02-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2019.1654070 |
| _version_ | 1797683604438908928 |
|---|---|
| author | Soheir Ghonemy Abeer Alarawi Hagar Bessar |
| author_facet | Soheir Ghonemy Abeer Alarawi Hagar Bessar |
| author_sort | Soheir Ghonemy |
| collection | DOAJ |
| description | Introduction Androgenetic alopecia is a stressful condition for males. Minoxidil 2% and 5% have been FDA approved for treatment of this condition. In literature, all studies have compared minoxidil 5% with 2%. Although other concentrations (2% to 12.5%) are available nowadays, we believe our study is the first to compare 10% versus 5% topical minoxidil in treatment of AGA. Objective To compare the efficacy and safety of 5% topical minoxidil with 10% topical minoxidil and placebo in AGA treatment. Materials and methods 36-weeks, double-blinded, placebo-controlled, randomized trial. A total of 90 men with AGA. First group have applied 5% minoxidil solution, second group applied 10% minoxidil solution; or third placebo group. Efficacy was evaluated clinically and trichoscopically. Results After 36 weeks of therapy; 5% topical minoxidil (0.47 ± 0.26) (0.59 ± 0.64) was significantly superior to 10% topical minoxidil (0.05 ± 0.13) (0.45 ± 0.74) and placebo (0.01 ± 0.05) (–0.03 ± 0.08) in terms of change from baseline in total vertex and frontal hair mean count respectively. Pull test change to negative in minoxidil 5%: (37%) patients after 6 month treatment, Minoxidil 10% group (37.5%) patients changed and in placebo group all patients after 6 month were the same (0%) change. No reported sexual dysfunction in all three groups. Conclusion Five percent of topical minoxidil was moderately superior to 10% topical minoxidil and placebo in increasing hair regrowth opposite to the expected, the irritation was marked for 10% topical minoxidil. Psychosocial stress after 10% usage were worsen by the shedding, irritation compared to their high expectation in comparison to 5% usage. |
| first_indexed | 2024-03-12T00:17:58Z |
| format | Article |
| id | doaj.art-53fd06c6c2b04cf489c8f216201fdd3c |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:17:58Z |
| publishDate | 2021-02-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-53fd06c6c2b04cf489c8f216201fdd3c2023-09-15T14:23:03ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532021-02-0132223624110.1080/09546634.2019.16540701654070Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluationSoheir Ghonemy0Abeer Alarawi1Hagar Bessar2Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Zagazig UniversityDepartment of Dermatology, Venereology and Andrology, Faculty of Medicine, Zagazig UniversityDepartment of Dermatology, Venereology and Andrology, Faculty of Medicine, Zagazig UniversityIntroduction Androgenetic alopecia is a stressful condition for males. Minoxidil 2% and 5% have been FDA approved for treatment of this condition. In literature, all studies have compared minoxidil 5% with 2%. Although other concentrations (2% to 12.5%) are available nowadays, we believe our study is the first to compare 10% versus 5% topical minoxidil in treatment of AGA. Objective To compare the efficacy and safety of 5% topical minoxidil with 10% topical minoxidil and placebo in AGA treatment. Materials and methods 36-weeks, double-blinded, placebo-controlled, randomized trial. A total of 90 men with AGA. First group have applied 5% minoxidil solution, second group applied 10% minoxidil solution; or third placebo group. Efficacy was evaluated clinically and trichoscopically. Results After 36 weeks of therapy; 5% topical minoxidil (0.47 ± 0.26) (0.59 ± 0.64) was significantly superior to 10% topical minoxidil (0.05 ± 0.13) (0.45 ± 0.74) and placebo (0.01 ± 0.05) (–0.03 ± 0.08) in terms of change from baseline in total vertex and frontal hair mean count respectively. Pull test change to negative in minoxidil 5%: (37%) patients after 6 month treatment, Minoxidil 10% group (37.5%) patients changed and in placebo group all patients after 6 month were the same (0%) change. No reported sexual dysfunction in all three groups. Conclusion Five percent of topical minoxidil was moderately superior to 10% topical minoxidil and placebo in increasing hair regrowth opposite to the expected, the irritation was marked for 10% topical minoxidil. Psychosocial stress after 10% usage were worsen by the shedding, irritation compared to their high expectation in comparison to 5% usage.http://dx.doi.org/10.1080/09546634.2019.1654070agaminoxidil 5%minoxidil 10%trichoscopic evaluation of aga |
| spellingShingle | Soheir Ghonemy Abeer Alarawi Hagar Bessar Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation Journal of Dermatological Treatment aga minoxidil 5% minoxidil 10% trichoscopic evaluation of aga |
| title | Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation |
| title_full | Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation |
| title_fullStr | Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation |
| title_full_unstemmed | Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation |
| title_short | Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation |
| title_sort | efficacy and safety of a new 10 topical minoxidil versus 5 topical minoxidil and placebo in the treatment of male androgenetic alopecia a trichoscopic evaluation |
| topic | aga minoxidil 5% minoxidil 10% trichoscopic evaluation of aga |
| url | http://dx.doi.org/10.1080/09546634.2019.1654070 |
| work_keys_str_mv | AT soheirghonemy efficacyandsafetyofanew10topicalminoxidilversus5topicalminoxidilandplacebointhetreatmentofmaleandrogeneticalopeciaatrichoscopicevaluation AT abeeralarawi efficacyandsafetyofanew10topicalminoxidilversus5topicalminoxidilandplacebointhetreatmentofmaleandrogeneticalopeciaatrichoscopicevaluation AT hagarbessar efficacyandsafetyofanew10topicalminoxidilversus5topicalminoxidilandplacebointhetreatmentofmaleandrogeneticalopeciaatrichoscopicevaluation |